Posted by Michael Wonder on 28 Feb 2026
FDA approves Novo Nordisk's Sogroya as the first and only once weekly, long-acting growth hormone for three additional paediatric indications
27 February 2026 - Novo Nordisk today announced that the US FDA has approved three new indications for once weekly Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone.
Sogroya is now indicated for children aged 2.5 years and older with Idiopathic short stature, short stature born small for gestational age and with no catch-up growth by 2 years of age, or growth failure associated with Noonan syndrome.
